PD-L1 INHIBITOR ATEZOLIZUMAB▼ - FOR NSCLC TREATMENT AFTER PRIOR CHEMOTHERAPY

Abstract

Atezolizumab – PD-L1 inhibitor, approwed for the second line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). Approval was based on its clinical benefit in phase II and phase III trials, in which atezolizumab significantly prolonged overall survival relative to docetaxel, regardless of PD-L1 status and was related with less adverse events. It is safe and effective immunotherapy drug for NSCLC patient with disease progression who have previously received platinum baced chemotherapy.